Pharmacogenomic Effect/ADR for Lapatinib (DBSNPE000265)

Identifier
DBSNPE000265
Drug
DB01259 (Lapatinib)
Interacting Gene/Enzyme
Tenascin-X
Gene Name
TNXB
UniProt ID
P22105
Defining Change(s)
T > Crs12153855
Allele Name
Not Available
Genotype(s)
(C;C) / (C;T)
Type(s)
ADR Directly Studied
Groups
Not Available
Description
The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.
References
  1. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR: HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18. [PubMed:21245432]